Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 19/20 | 0.62 |
| ▸ | KCNJ1 | P48048 | 16/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14782838 | 0.88 | KCNH2 (0.73) | KCNH2KCNJ1SLC6A4 | |
| SCHEMBL14790591 | 0.88 | KCNH2 (0.60) | KCNH2KCNJ1 | |
| SCHEMBL14785759 | 0.87 | KCNJ1 (0.64) | KCNH2KCNJ1 | |
| SCHEMBL4549530 | 0.86 | KCNJ1 (0.82) | KCNH2KCNJ1SLC6A4 | |
| SCHEMBL14785896 | 0.83 | KCNH2 (0.54) | KCNH2KCNJ1 | |
| SCHEMBL14782755 | 0.83 | KCNH2 (0.54) | KCNH2KCNJ1 | |
| SCHEMBL14785694 | 0.81 | KCNH2 (0.52) | KCNH2KCNJ1 | |
| SCHEMBL14785925 | 0.81 | KCNJ1 (0.60) | KCNH2KCNJ1 | |
| SCHEMBL14782884 | 0.79 | KCNH2 (0.52) | KCNH2KCNJ1 | |
| SCHEMBL14785829 | 0.79 | KCNJ1 (0.54) | KCNH2KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755656-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2016-09-07 | — | — | EP | claimed |
| US-20140235628-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2014-08-21 | — | — | US | claimed |
| EP-2755656-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2014-07-23 | — | — | EP | claimed |
| WO-2013039802-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-03-21 | — | — | WO | claimed |
| US-9527830-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527830-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527830-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2755656-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2016-09-07 | — | — | EP | disclosed |
| EP-2755656-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20140235628-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2014-08-21 | — | — | US | disclosed |
| US-20140235628-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2014-08-21 | — | — | US | disclosed |
| US-20140235628-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2014-08-21 | — | — | US | disclosed |
| EP-2755656-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013039802-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013039802-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235628-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | KCNH2 16/4885KCNJ1 2/4885SLC6A4 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.